S&P 500   3,851.85
DOW   31,188.38
QQQ   324.03
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.03
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.03
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.03
Log in
NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$73.41
-0.44 (-0.60 %)
(As of 01/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$71.84
Now: $73.41
$74.93
50-Day Range
$56.70
MA: $62.88
$77.16
52-Week Range
$27.46
Now: $73.41
$77.89
Volume12,799 shs
Average Volume675,437 shs
Market Capitalization$3.19 billion
P/E Ratio25.85
Dividend YieldN/A
Beta1.27
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Pacira BioSciences logo

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

296th out of 1,928 stocks

Pharmaceutical Preparations Industry

150th out of 774 stocks

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.8 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Employees606

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.72 per share
Book Value$8.51 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Market Cap$3.19 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$73.41
-0.44 (-0.60 %)
(As of 01/20/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

How has Pacira BioSciences' stock been impacted by Coronavirus (COVID-19)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 106.7% and is now trading at $72.74.
View which stocks have been most impacted by COVID-19
.

Is Pacira BioSciences a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Pacira BioSciences' CEO?

1,428 employees have rated Pacira BioSciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Pacira BioSciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Thursday, October, 29th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.03. The firm earned $117.50 million during the quarter, compared to the consensus estimate of $115.95 million. Pacira BioSciences had a return on equity of 10.71% and a net margin of 29.95%. The company's revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.48 EPS.
View Pacira BioSciences' earnings history
.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $429.6-429.6 million, compared to the consensus revenue estimate of $427.7 million.

What price target have analysts set for PCRX?

12 Wall Street analysts have issued twelve-month price objectives for Pacira BioSciences' stock. Their forecasts range from $48.00 to $90.00. On average, they expect Pacira BioSciences' stock price to reach $70.08 in the next twelve months. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for Pacira BioSciences
or view Wall Street analyst' top-rated stocks.

Who are some of Pacira BioSciences' key competitors?

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 71, Pay $1.47M)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 60, Pay $637.22k)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 47, Pay $727.97k)
  • Dr. Roy Winston, Chief Clinical Officer (Age 60, Pay $647.06k)
  • Mr. Max Reinhardt, Pres of ROW (Age 50, Pay $619.19k)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 42)
  • Mr. Charles Laranjeira, Chief Technical Officer (Age 55)
  • Susan Mesco, Head of Investor Relations
  • Mr. Richard Kahr, VP of HR
  • Mr. Robert J. Weiland, Sr. VP of Alliance Management (Age 61)

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (2.38%), Peregrine Capital Management LLC (0.51%), Tributary Capital Management LLC (0.35%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.05%) and HGK Asset Management Inc. (0.03%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark A Kronenfeld, Max Reinhardt, Paul J Hastings, Richard Scranton and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Peregrine Capital Management LLC, and State of Alaska Department of Revenue. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Crossmark Global Holdings Inc., HGK Asset Management Inc., First Hawaiian Bank, and Louisiana State Employees Retirement System. Company insiders that have bought Pacira BioSciences stock in the last two years include Mark A Kronenfeld, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $72.74.

How big of a company is Pacira BioSciences?

Pacira BioSciences has a market capitalization of $3.16 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira BioSciences employs 606 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.